Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab is to continue to receive pembrolizumab for up to 27 weeks after surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation is as good as receiving pembrolizumab for 27 weeks after surgery in triple-negative breast cancer patients who achieved a pathologic complete response after preoperative treatment with chemotherapy and pembrolizumab.
Inclusion Criteria
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Triple Negative Breast Cancer: * Patients with a history of clinical stage T1cN1-2 or T2-4N0-2 (clinical stage II or III prior to preoperative therapy) breast cancer at time of diagnosis, according to the primary tumor-regional lymph node anatomic staging criteria of the American Joint Committee on Cancer (AJCC) 8th edition, as determined by the investigator in radiologic assessment, clinical assessment or both * Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Isolated tumor cells are considered node-negative * Estrogen receptor (ER) and progesterone receptor (PR) =< 10%; HER2-negative by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (immunohistochemistry [IHC] and fluorescence in situ hybridization [FISH]) * If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts
- Patients must have received neoadjuvant chemotherapy in combination with pembrolizumab for a minimum of 6 cycles. All systemic chemotherapy must have been completed preoperatively
- An interval of no more than 12 weeks between the completion date of the final surgery and the date of randomization * Note: Adjuvant radiation can be given on study; however, it is recommended to complete adjuvant radiation prior to registration. If radiation is given on study, it is encouraged to be given concurrently with pembrolizumab if the patient is on the pembrolizumab arm, per investigator discretion. Treatment with adjuvant pembrolizumab is strongly discouraged prior to participation in this trial, but if administered (e.g., if patients are awaiting pathology results), pembrolizumab may be administered for up to 6 weeks (i.e., up to 2 q3week doses or up to one q6week dose) post-surgery and must be completed prior to registration
- Use of investigational anti-cancer agents must be discontinued at time of registration
- Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows: * Breast surgery: Total mastectomy or breast-conserving surgery with histologically negative margins, including no ink on tumor for DCIS, at the time of excision ** For patients who undergo breast-conserving surgery, the margins of the resected specimen must be histologically free of ductal carcinoma in-situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates DCIS at the line of resection, additional operative procedures may be performed to obtain clear margins. If DCIS is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. Patients with margins positive for classic lobular carcinoma in situ (LCIS) are eligible without additional resection * Lymph node surgery: ** For a patient with clinically N0 disease, a sentinel lymph node biopsy should have been performed at time of surgical evaluation, and if pathologically node positive, the patient is no longer eligible. Isolated tumor cells are considered node-negative ** For a patient with clinically N1 disease at diagnosis (with positive results from a fine-needle aspiration, core biopsy, or sentinel node biopsy performed prior to preoperative therapy) additional surgical evaluation of the axilla following preoperative therapy is required *** If they become cN0 (no palpable adenopathy), then a sentinel lymph node biopsy could have been performed at time of surgery (axillary dissection would also be permitted); if the sentinel lymph node biopsy is positive, the patient is no longer eligible ** If sentinel node biopsy performed before preoperative therapy was negative, no additional surgical evaluation of the axilla is required after preoperative therapy. If sentinel node biopsy performed before preoperative therapy was positive, an ALND is required after preoperative therapy ** If the only sentinel node identified by isotope scan is in the internal mammary chain, surgical evaluation of the axilla is still required ** If sentinel node evaluation after preoperative therapy is negative, no further additional surgical evaluation of the axilla is required ** Axillary dissection without sentinel node evaluation is permitted as the initial or sole axillary evaluation after preoperative therapy
- If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible
- Not pregnant and not nursing, because this study involves an agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test done =< 7 days prior to randomization is required
- Absolute neutrophil count (ANC) >= 1,000/mm^3
- Platelet Count >= 100,000/mm^3
- Estimated glomerular filtration rate (eGFR) >= 15 mL/min/1.73m^2
- Total Bilirubin =< 1.5 x upper limit of normal (ULN) * Patients with Gilbert’s disease with a total bilirubin =< 2.5 x ULN and direct bilirubin within normal limits are permitted
- Aspartate aminotransferase (AST) serum aspartate aminotransferase [SGOT] / alanine aminotransferase (ALT) serum glutamic pyruvic transaminase [SGPT] =< 3 x institutional ULN
- Patients must be willing to provide tumor tissue from the diagnostic core biopsy. If inadequate tumor tissue is available, patients are still eligible to participate in the trial
- No stage IV (metastatic) breast cancer
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- No history of any prior (ipsi- or contralateral) invasive breast cancer. Prior DCIS is allowed
- No evidence of recurrent disease following preoperative therapy and surgery
- No known active liver disease, e.g. due to hepatitis B virus (HBV), hepatitis C virus (HCV), autoimmune hepatic disorders, or sclerosing cholangitis
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- Patients with known HIV infection who are on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
- No history of intolerance, including grade 3 or 4 infusion reaction or hypersensitivity to pembrolizumab or murine proteins or any components of the product * Note: Prior immune-related adverse events (irAEs) are allowed if they resolved to ≤ grade 1 and the patient tolerated subsequent therapy without requiring chronic steroids for the irAE
- No medical conditions that require chronic systemic steroids (> 10 mg prednisone daily or equivalent) or any other form of immunosuppressive medications and has required such therapy in the last two years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic therapy
- Patients who are unable or unwilling to comply with the requirements of the protocol per investigator assessment are not eligible
Additional locations may be listed on ClinicalTrials.gov for NCT05812807.
Locations matching your search criteria
United States
Alabama
Fairhope
Mobile
Alaska
Anchorage
Arizona
Goodyear
Kingman
Phoenix
Arkansas
Fayetteville
Jonesboro
Little Rock
Rogers
Springdale
California
Arroyo Grande
Beverly Hills
Cameron Park
Carmichael
Chico
Dublin
Elk Grove
Emeryville
Fremont
Fresno
Loma Linda
Los Angeles
Marysville
Modesto
Oakland
Orange
Palm Springs
Palo Alto
Pasadena
Rocklin
Roseville
Sacramento
Salinas
San Francisco
San Jose
San Leandro
San Mateo
San Rafael
Santa Clara
Santa Monica
Santa Rosa
South San Francisco
Tarzana
Torrance
Truckee
Vallejo
Walnut Creek
Woodland
Colorado
Aurora
Colorado Springs
Denver
Highlands Ranch
Lafayette
Littleton
Lone Tree
Parker
Connecticut
Bridgeport
Danbury
Derby
Fairfield
Glastonbury
Greenwich
Guilford
Hartford
Meriden
New Britain
New Haven
North Haven
Norwalk
Stamford
Torrington
Trumbull
Waterbury
Waterford
Delaware
Millville
Newark
Rehoboth Beach
District of Columbia
Washington
Florida
Bonita Springs
Clearwater
Fort Lauderdale
Fort Myers
Hollywood
Jacksonville
Miami Beach
Ocoee
Orlando
Pembroke Pines
Safety Harbor
Tallahassee
Tampa
Georgia
Albany
Athens
Atlanta
Augusta
Decatur
Duluth
Johns Creek
Lawrenceville
Savannah
Hawaii
Aiea
Ewa Beach
Honolulu
Idaho
Boise
Caldwell
Coeur D'Alene
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Aurora
Barrington
Bloomington
Canton
Carterville
Carthage
Centralia
Chicago
Crystal Lake
Danville
DeKalb
Decatur
Dixon
Downers Grove
Effingham
Elgin
Eureka
Evanston
Galesburg
Geneva
Glenview
Grayslake
Harvey
Hazel Crest
Highland Park
Kewanee
Lake Forest
Libertyville
Macomb
Mattoon
Maywood
Moline
Mount Vernon
New Lenox
O'Fallon
Oak Brook
Oak Lawn
Orland Park
Ottawa
Park Ridge
Pekin
Peoria
Peru
Princeton
Rockford
Springfield
Urbana
Warrenville
Washington
Indiana
Avon
Carmel
Crown Point
Dyer
Fort Wayne
Hobart
Indianapolis
Munster
New Albany
South Bend
Valparaiso
Iowa
Ankeny
Bettendorf
Carroll
Cedar Rapids
Clive
Council Bluffs
Des Moines
Fort Dodge
Iowa City
Waukee
Kansas
Chanute
Dodge City
El Dorado
Hays
Independence
Kansas City
Kingman
Lawrence
Liberal
McPherson
Newton
Olathe
Overland Park
Parsons
Pratt
Salina
Topeka
Wellington
Westwood
Wichita
Winfield
Kentucky
Corbin
Elizabethtown
Lexington
Louisville
Louisiana
Baton Rouge
Covington
Houma
New Orleans
Shreveport
Maryland
Annapolis
Baltimore
Bethesda
Frederick
Gaithersburg
Glen Burnie
Largo
Lutherville
Westminster
Massachusetts
Boston
Foxborough
Methuen
South Weymouth
Springfield
Michigan
Ann Arbor
Battle Creek
Brighton
Canton
Chelsea
Clinton Township
Detroit
East China
Flint
Grand Rapids
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Livonia
Macomb Township
Muskegon
Niles
Norton Shores
Novi
Pontiac
Reed City
Saginaw
Saint Joseph
Southfield
Tawas City
Traverse City
Warren
West Bloomfield
West Branch
Wyoming
Ypsilanti
Minnesota
Bemidji
Brainerd
Burnsville
Coon Rapids
Deer River
Duluth
Edina
Hibbing
Maplewood
Minneapolis
Robbinsdale
Rochester
Saint Cloud
Saint Louis Park
Saint Paul
Sandstone
Thief River Falls
Virginia
Worthington
Mississippi
Columbus
Grenada
Jackson
New Albany
Oxford
Southhaven
Missouri
Ballwin
Cape Girardeau
Columbia
Creve Coeur
Farmington
Independence
Kansas City
Lee's Summit
North Kansas City
Osage Beach
Rolla
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Montana
Anaconda
Billings
Bozeman
Great Falls
Kalispell
Missoula
Nebraska
Bellevue
Hastings
Kearney
Omaha
Nevada
Henderson
Las Vegas
Reno
New Hampshire
Concord
Lebanon
Londonderry
Manchester
New Jersey
Camden
Cherry Hill
Englewood
Hackensack
Hamilton
Jersey City
Lakewood
Livingston
Long Branch
Morristown
Mullica Hill
New Brunswick
Paramus
Ridgewood
Sewell
Somerville
Summit
New Mexico
Albuquerque
Rio Rancho
New York
Bay Shore
Bronx
Brooklyn
Camillus
East Syracuse
Greenlawn
Jamaica
Lake Success
Mineola
Mount Kisco
New York
Poughkeepsie
Rochester
Sleepy Hollow
Southampton
Staten Island
Stony Brook
Webster
North Carolina
Albemarle
Asheboro
Burlington
Cary
Chapel Hill
Charlotte
Clemmons
Concord
Durham
Forest City
Garner
Gastonia
Greensboro
Greenville
Hendersonville
Huntersville
Kernersville
Lincolnton
Matthews
Monroe
Mooresville
Mount Airy
Pinehurst
Raleigh
Reidsville
Salisbury
Shelby
Thomasville
Washington
Winston-Salem
North Dakota
Bismarck
Fargo
Ohio
Akron
Athens
Barberton
Belpre
Centerville
Chillicothe
Cincinnati
Columbus
Dayton
Delaware
Dublin
Franklin
Greenville
Grove City
Lancaster
Mansfield
Marion
Marysville
Medina
Newark
Perrysburg
Pickerington
Portsmouth
Springfield
Sylvania
Toledo
Troy
West Chester
Westerville
Zanesville
Oklahoma
Oklahoma City
Tulsa
Oregon
Bend
Clackamas
Grants Pass
Gresham
Medford
Newberg
Ontario
Oregon City
Portland
Tualatin
Pennsylvania
Allentown
Bethlehem
Chambersburg
Danville
Dickson City
East Stroudsburg
Ephrata
Erie
Gettysburg
Hazleton
Hershey
Jefferson Hills
Lebanon
Lewisburg
Meadville
Monroeville
Philadelphia
Pittsburgh
Reading
Sayre
Scranton
West Reading
Wexford
Wilkes-Barre
Willow Grove
York
Puerto Rico
Manati
San Juan
Rhode Island
Providence
Westerly
South Carolina
Bluffton
Boiling Springs
Charleston
Easley
Florence
Georgetown
Greenville
Greenwood
Greer
Hilton Head Island
Rock Hill
Seneca
West Columbia
South Dakota
Aberdeen
Pierre
Sioux Falls
Tennessee
Collierville
Knoxville
Memphis
Nashville
Texas
Baytown
Conroe
Cypress
Dallas
Fort Worth
Houston
League City
Nassau Bay
Richardson
Sugar Land
The Woodlands
Vermont
Berlin
Burlington
Virginia
Fairfax
Falls Church
Fishersville
Lynchburg
McLean
Mechanicsville
Midlothian
Richmond
Woodbridge
Washington
Bellevue
Edmonds
Issaquah
Kirkland
Renton
Seattle
Vancouver
Yakima
West Virginia
Bridgeport
Huntington
Morgantown
Parkersburg
Wisconsin
Antigo
Appleton
Ashland
Berlin
Brookfield
Burlington
Chilton
Eau Claire
Franklin
Germantown
Grafton
Green Bay
Janesville
Johnson Creek
Kenosha
La Crosse
Madison
Marinette
Marshfield
Medford
Menomonee Falls
Mequon
Milwaukee
Minocqua
Mukwonago
Neenah
New London
Oak Creek
Oconomowoc
Oconto Falls
Oshkosh
Racine
Rhinelander
Rice Lake
Shawano
Sheboygan
Stevens Point
Sturgeon Bay
Summit
Two Rivers
Waukesha
Waupaca
Wausau
Wauwatosa
West Allis
West Bend
Weston
Wisconsin Rapids
PRIMARY OBJECTIVES:
I. To evaluate whether observation results in a non-inferior recurrence-free survival (RFS) compared to adjuvant pembrolizumab in early-stage triple-negative breast cancer (TNBC) patients who achieve a pathologic complete response (pCR) after neoadjuvant chemotherapy with pembrolizumab.
II. To compare quality of life (QOL) at approximately 27 weeks as assessed by the Functional Assessment of Cancer Therapy-Breast (FACT-B) Trial Outcome Index between patients randomized to adjuvant pembrolizumab versus observation. (Quality of Life)
III. To assess the social value of de-escalation of adjuvant breast cancer immunotherapy at approximately 27 weeks and, by modeling, over a lifetime. (Value of Care)
SECONDARY OBJECTIVES:
I. To evaluate whether observation compared to adjuvant pembrolizumab impacts the following:
Ia. RFS by stage at presentation and by receipt of prior anthracycline therapy;
Ib. Adverse event rate: difference in grade 3 or higher adverse event rates overall and grade 3 or higher immune-related adverse events (irAEs) rates;
Ic. Overall survival (OS);
Id. Locoregional recurrence (LRR, both isolated LRR as first events and LRR events simultaneous with distant metastasis [DM]);
Ie. RFS, LRR, OS, adverse events, and QOL by age (=< 45, 46-65, and > 65), race, and ethnicity;
If. Adverse events related to receipt of radiotherapy.
II. To assess the value of de-escalation of breast cancer immunotherapy from the payer perspective at approximately 27 weeks and, by modelling, over a lifetime. (Value of Care)
III. To compare patient out-of-pocket costs at approximately 27 weeks between patients randomized to adjuvant pembrolizumab versus observation. (Value of Care)
IV. To compare financial toxicity at approximately 27 weeks between patients randomized to adjuvant pembrolizumab versus observation. (Value of Care)
V. To compare work/productivity impairment at approximately 27 weeks between patients randomized to adjuvant pembrolizumab versus observation. (Value of Care)
EXPLORATORY OBJECTIVES:
I. To describe trajectories of QOL over time among patients randomized to adjuvant pembrolizumab versus (vs.) observation. (Quality of Life)
II. To compare various QOL domains after approximately 27 weeks as assessed by the 5 subscales of the FACT-B Index between patients randomized to adjuvant pembrolizumab versus observation. (Quality of Life)
III. To compare self-reported symptomatic adverse events at approximately 27 weeks assessed by the patient reported outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) between patients randomized to adjuvant pembrolizumab versus observation. (Quality of Life)
IV. To describe trajectories of financial toxicity and work/productivity impairment over time from baseline to approximately 27 weeks among patients randomized to adjuvant pembrolizumab versus observation. (Value of Care)
V. To develop and assess a measure of value from the patient perspective at approximately 27 weeks. (Value of Care)
OUTLINE: Patients are randomized to 1 of 2 arms after completing neoadjuvant chemotherapy in combination with pembrolizumab, followed by definitive breast surgery.
ARM I (PEMBROLIZUMAB): Patients receive pembrolizumab intravenously (IV) over 25-40 minutes once every 3 weeks (Q3W) or once every 6 weeks (Q6W) for 27 weeks. Patients also undergo tumor biopsy and collection of blood throughout the study. Patients also undergo mammography, breast ultrasound or magnetic resonance imaging (MRI) during follow-up.
ARM II (OBSERVATION): Patients undergo observation for 27 weeks. Patients also undergo tumor biopsy and collection of blood throughout the study. Patients also undergo mammography, breast ultrasound or MRI during follow-up.
Patients will be followed every 6 months for 5 years after registration or recurrence. Thereafter, patients will be followed annually for overall survival for a total of 10 years after registration.
Trial PhasePhase III
Trial Typetreatment
Lead OrganizationAlliance for Clinical Trials in Oncology
Principal InvestigatorSara Michell Tolaney
- Primary IDA012103
- Secondary IDsNCI-2022-07859
- ClinicalTrials.gov IDNCT05812807